NCT04070378View on ClinicalTrials.gov

Study of Daratumumab in Patients With Mild to Moderate Alzheimer's Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

November 6, 2019

Primary Completion Date

June 8, 2023

Study Completion Date

August 15, 2023

Conditions
Alzheimer Disease
Interventions
DRUG

Daratumumab Injection

Daratumumab SC 1800 mg (daratumumab 1800 mg with rHuPH20 30,000 units) subcutaneous infusion

Trial Locations (1)

11030

The Litwin-Zucker Research Center, Manhasset

All Listed Sponsors
collaborator

Janssen Scientific Affairs, LLC

INDUSTRY

lead

Marc L Gordon, MD

OTHER

NCT04070378 - Study of Daratumumab in Patients With Mild to Moderate Alzheimer's Disease | Biotech Hunter | Biotech Hunter